Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IDIBELL licenses Histocell a Patent for Acute Respiratory Diseases with Stem Cells

Published: Wednesday, March 27, 2013
Last Updated: Wednesday, March 27, 2013
Bookmark and Share
It is a "smart drug" that can reduce inflammation and regenerate damaged tissue.

The product has given good results in animals to treat acute respiratory distress and some forms of asthma and could be effective for other acute or chronic lung diseases.

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells. These cells, administered intravenously, have the ability to go directly to the damaged lungs, acting as a "smart drug".

To enhance the effect, researchers have modified this cells by genetic engineering. The studies have been developed by a team led by Josep Maria Aran, researcher at the Human Molecular Genetics group of IDIBELL, in collaboration with researchers of the Pneumology group at Vall d'Hebron Research Institute (VHIR) and the Biomedical Research Network Centre for Respiratory Diseases (CIBERES). The outcomes of the research have supposed an international patent application managed by the Technology Transfer Office (TTO) at IDIBELL.

The researchers use adult mesenchymal stem cells extracted from adipose tissue obtained from liposuction. These cells are capable of enhancing the regeneration of the damaged lung tissue and secrete inflammatory proteins therein when injected into the blood.

Improvements

The novelty patented by IDIBELL and VHIR researchers has been the insertion of improvements through genetic engineering that can significantly enhance the anti-inflammatory and regenerative power of the mesenchymal cells. Specifically, researchers have modified the antagonist to secrete interleukin 33, a regulatory protein (cytokine) that has a fundamental role in the inflammatory process.
 
The treatment has proven to be very effective given intravenously, although it could be considered the option of administering it by inhalation.

In the administered dose, these stem cells do not involve immune rejection, because the body removes them after their function is performed. This makes them particularly useful for treating acute diseases.

Good results

The licensed product to Histocell has been successful in experiments on animals with acute respiratory distress, a very severe respiratory failure without effective treatment. It has also been proven effective in animal models with allergic asthma to persulfate salts, a condition equivalent to a professional disease detected among professional hairdressers. The researcher Josep Maria Aran stresses that the new technology could also have applications in other acute and even chronic conditions such as emphysema.

In any case, many years will be needed before the product can be applied in humans. It will require additional preclinical studies and clinical trials in people. In this sense, the patent licensed to Histocell is essential to complete these studies and bring the product to market.

Get to market

The head of the TTO at IDIBELL, Montse Ballarín, highlights the fact that "the licensed products developed at our institution reflect the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market and, ultimately, to develop products at the service of society”.

Histocell is a biopharmaceutical company based in the Basque Country (Spain) specialised in tissue engineering and in cell therapy. The company is dedicated to developing innovative products in the field of regenerative medicine. It has a cleanroom for developing cell therapy products based on tissue engineering. The company has four therapeutic programs: bone and joint regeneration, neuroprotection in spinal cord injury and pulmonary therapy.

The development of the patent transferred to Histocell has been possible thanks to the funding of the Spanish Ministry of Economy and Competitiveness, the Instituto de Salud Carlos III and the European funds for regional development (ERDF).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genetically Modified Stem Cells are Effective Against Acute Respiratory Diseases
Administration of genetically modified mesenchymal stem cells regenerates lung tissue and stops the inflammatory process in mice with acute lung injury.
Tuesday, June 18, 2013
IDIBELL and VHIR licenses Histocell a Patent for Acute Respiratory Diseases with Stem Cells
It is a "smart drug" that can reduce inflammation and regenerate damaged tissue.
Tuesday, April 09, 2013
IDIBELL Licenses Histocell a Patent for Acute Respiratory Diseases with Stem Cells
It is a "smart drug" that can reduce inflammation and regenerate damaged tissue.
Wednesday, April 03, 2013
Scientific News
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
New Mechanism of Tuberculosis Infection
Researchers have identified a new infection mechanism of tuberculosis that could lead to a new therapeutic angle.
Modelling ALS Requires ‘Aged’ Stem Cells
Research suggests engineered cells are too ‘young’ to accurately model ALS and should be 'aged' to speed progress toward finding potential treatments.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Rapid Generation from Stem Cells
Researchers coax human stem cells to rapidly generate bone and heart muscle by directing stem cells down complex developmental pathways.
HIV Hides No Longer
Researchers are working to create proteins that clear HIV-infected cells in order to eliminate latent infection and dormancy.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!